Extrahepatic Cholangiocarcinoma Clinical Trial
— VEGF ECCOfficial title:
VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
The investigators study the VEGF signaling in ECC cell lines,patients and its mechanism in ECC growth, proliferation and apoptosis.
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | September 2014 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Extrahepatic cholangiocarcinoma patients diagnosed through biopsy; two or more dynamic imagine with a diagnosis of Extrahepatic cholangiocarcinoma 2. Child-Pugh A or B 3. well preserved renal and hematopoietic Function 4. receive surgical therapy 5. achieve complete section accessed by contrast-enhanced CT Exclusion Criteria: 1. incomplete section 2. remote metastasis 3. Child-Pugh C 4. combination with other hepatobiliary disease 5. suffer from other tumors concurrently or in last five years |
Observational Model: Case Control, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
China | First Affiliated Hospital, Sun Yat-Sen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
First Affiliated Hospital, Sun Yat-Sen University | Guangdong Province, Department of Science and Technology |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the variation of the quantity of VEGF signal pathway genes in normal liver tissue,peri tumor,tumor and metastasis. | the sections would be collected as previously described.Western blot,immunohistochemistry,PCR would be conducted to find out the variation between the normal liver tissue and tumor,tumor and meta(if have). | the day when conducting surgery (day 1) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05009953 -
Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT06101277 -
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
|
N/A | |
Recruiting |
NCT05448183 -
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic Cholangiocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT04333927 -
Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
|
Phase 2 | |
Recruiting |
NCT04561453 -
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
|
||
Not yet recruiting |
NCT06440993 -
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
|
Phase 2 | |
Recruiting |
NCT05519319 -
Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma
|
N/A | |
Enrolling by invitation |
NCT05233293 -
Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma
|
N/A | |
Recruiting |
NCT05712356 -
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
|
Phase 2 |